open access

Vol 67, No 12 (2009)
Other
Published online: 2009-12-30
Submitted: 2012-12-28
Get Citation

Original article
Asymmetric dimethylarginine levels in patients with coronary artery ectasia

Serkan Cay, Goksel Cagirci, Murat Akcay, Ozlem Karakurt, Erkan Kahraman, Nuray Yazihan, Aytun Canga, Ramazan Akdemir, Sinan Aydogdu
Kardiol Pol 2009;67(12):1362-1368.

open access

Vol 67, No 12 (2009)
Other
Published online: 2009-12-30
Submitted: 2012-12-28

Abstract

Background: Endothelial dysfunction might be one of the pathophysiological mechanisms in the development of coronary artery ectasia (CAE) although the exact mechanisms have not yet been demonstrated. Asymmetric dimethylarginine (ADMA), an endogenous competitive inhibitor of nitric oxide synthase, is also related to endothelial and structural dysfunction.
Aim: To asses the relationship between CAE and ADMA plasma concentrations.
Methods: Thirty patients with CAE in a mean age of 55.5 ± 3.6 years and 40 patients with normal coronary arteries in a mean age of 53.3 ± 11.6 years were studied. The ADMA levels of all patients were analysed by ELISA method.
Results: The mean ADMA level in the CAE group was found to be significantly higher than the mean ADMA level in the normal coronary artery group (2.26 ± 0.47 vs. 1.43 ± 0.40 µmol/l, p < 0.001). The elevated ADMA level (> 1.80 µmol/l) was present in 83.0% of patients from the CAE group and 25.0% of patients from the normal coronary artery group (p < 0.001). Having an increased ADMA level enhanced the risk of CAE 15-fold. The multiple-adjusted OR of the risk of CAE was 18.71 (95% CI 4.95-70.68) for the higher ADMA level compared to the lower level.
Conclusion: Asymmetric dimethylarginine level is significantly associated with the presence of coronary artery ectasia. These findings suggest that increased ADMA level may be associated with endothelial dysfunction leading to the development of coronary artery ectasia.

Abstract

Background: Endothelial dysfunction might be one of the pathophysiological mechanisms in the development of coronary artery ectasia (CAE) although the exact mechanisms have not yet been demonstrated. Asymmetric dimethylarginine (ADMA), an endogenous competitive inhibitor of nitric oxide synthase, is also related to endothelial and structural dysfunction.
Aim: To asses the relationship between CAE and ADMA plasma concentrations.
Methods: Thirty patients with CAE in a mean age of 55.5 ± 3.6 years and 40 patients with normal coronary arteries in a mean age of 53.3 ± 11.6 years were studied. The ADMA levels of all patients were analysed by ELISA method.
Results: The mean ADMA level in the CAE group was found to be significantly higher than the mean ADMA level in the normal coronary artery group (2.26 ± 0.47 vs. 1.43 ± 0.40 µmol/l, p < 0.001). The elevated ADMA level (> 1.80 µmol/l) was present in 83.0% of patients from the CAE group and 25.0% of patients from the normal coronary artery group (p < 0.001). Having an increased ADMA level enhanced the risk of CAE 15-fold. The multiple-adjusted OR of the risk of CAE was 18.71 (95% CI 4.95-70.68) for the higher ADMA level compared to the lower level.
Conclusion: Asymmetric dimethylarginine level is significantly associated with the presence of coronary artery ectasia. These findings suggest that increased ADMA level may be associated with endothelial dysfunction leading to the development of coronary artery ectasia.
Get Citation

Keywords

asymmetric dimethylarginine; coronary artery ectasia; endothelial dysfunction

About this article
Title

Original article
Asymmetric dimethylarginine levels in patients with coronary artery ectasia

Journal

Kardiologia Polska (Polish Heart Journal)

Issue

Vol 67, No 12 (2009)

Pages

1362-1368

Published online

2009-12-30

Bibliographic record

Kardiol Pol 2009;67(12):1362-1368.

Keywords

asymmetric dimethylarginine
coronary artery ectasia
endothelial dysfunction

Authors

Serkan Cay
Goksel Cagirci
Murat Akcay
Ozlem Karakurt
Erkan Kahraman
Nuray Yazihan
Aytun Canga
Ramazan Akdemir
Sinan Aydogdu

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl